Evolus, Inc. (EOLS) vs Alpha Teknova, Inc. (TKNO)

Evolus, Inc. and Alpha Teknova, Inc. are both Drug Manufacturers Specialty & Generic companies. Evolus, Inc. and Alpha Teknova, Inc. are of similar size ($519.2M and $498.8M). Evolus, Inc. grew revenue faster over the last twelve months: 13.9% against 12.3%. Evolus, Inc. has the higher net margin (−10.9% vs −38.4%) and the higher return on invested capital (−14.5% vs −16.9%). Across the 17 metrics below, Evolus, Inc. leads on 13 and Alpha Teknova, Inc. on 4.

Valuation

Metric EOLS TKNO Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.66 11.45 2.25
P/B n/m 7.99 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 2.02 11.45 2.56
Earnings yield (6.52%) (3.32%) (2.99%)
Free cash flow yield (4.17%) (1.47%) 0.00%

Profitability

Metric EOLS TKNO Drug Manufacturers Specialty & Generic median
Gross margin 66.74% 34.60% 53.94%
Operating margin (5.90%) (36.19%) 0.00%
Net margin (10.85%) (38.37%) 0.00%
Free cash flow margin (6.92%) (16.83%) 0.00%
Return on equity 138.57% (24.19%) (0.40%)
Return on assets (14.40%) (16.25%) (3.32%)
Return on invested capital (14.47%) (16.93%) 0.00%

Growth

Metric EOLS TKNO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 13.87% 12.27% 10.01%
EPS growth (last fiscal year) 1.23% 43.86% —
Revenue growth, 5-year CAGR 39.36% 5.30% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EOLS TKNO Drug Manufacturers Specialty & Generic median
Debt to equity (5.07) 0.21 0.05
Current ratio 1.70 4.49 2.31
Net debt to EBITDA (4.08) 0.75 0.85

Dividend

Metric EOLS TKNO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric EOLS TKNO Drug Manufacturers Specialty & Generic median
Market cap 519.16m 498.76m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack